Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer and other tumor types, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
The company's Compensation Committee granted stock options to purchase 14,000 shares to one newly hired employee under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.19 per share, matching the closing price on the grant date. The options feature a 10-year term with four-year vesting, including 25% vesting after the first year and the remaining 75% vesting monthly over three years, contingent on continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una societ脿 biofarmaceutica in fase clinica focalizzata sullo sviluppo di un inibitore WEE1 per il cancro ovarico e altri tipi di tumore, ha annunciato una concessione di incentivo ai sensi della Regola 5635(c)(4) del Nasdaq.
Il Comitato per la Remunerazione dell'azienda ha assegnato opzioni su azioni per l'acquisto di 14.000 azioni a un nuovo dipendente assunto, nell'ambito del Piano di Incentivi per l'Assunzione 2022. Le opzioni hanno un prezzo di esercizio di 1,19 $ per azione, corrispondente al prezzo di chiusura del giorno della concessione. Le opzioni prevedono un termine di 10 anni con maturazione in quattro anni, con il 25% delle azioni che matura dopo il primo anno e il restante 75% che matura mensilmente nei successivi tre anni, subordinatamente alla permanenza in azienda.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), una compa帽铆a biofarmac茅utica en etapa cl铆nica enfocada en desarrollar un inhibidor WEE1 para el c谩ncer de ovario y otros tipos de tumores, ha anunciado una concesi贸n de incentivo bajo la Regla 5635(c)(4) de Nasdaq.
El Comit茅 de Compensaci贸n de la empresa otorg贸 opciones sobre acciones para comprar 14,000 acciones a un empleado reci茅n contratado bajo el Plan de Incentivos por Contrataci贸n 2022. Las opciones tienen un precio de ejercicio de $1.19 por acci贸n, igualando el precio de cierre en la fecha de concesi贸n. Las opciones cuentan con un plazo de 10 a帽os con un per铆odo de adquisici贸n de cuatro a帽os, incluyendo un 25% que se adquiere despu茅s del primer a帽o y el 75% restante que se adquiere mensualmente durante los siguientes tres a帽os, condicionado a la continuidad laboral.
Zentalis Pharmaceuticals (雮橃姢雼�: ZNTL)電� 雮滌唽鞎� 氚� 旮绊儉 膦呾枒 鞙犿槙鞚� 鞙勴暅 WEE1 鞏奠牅鞝� 臧滊皽鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雮橃姢雼� 靸侅灔 攴滌爼 5635(c)(4)鞐� 霐半ジ 鞙犾澑 氤挫“旮�(inducement grant)鞚� 氚滍憸頄堨姷雼堧嫟.
須岇偓鞚� 氤挫儊鞙勳洂須岆姅 2022雲� 瓿犾毄 鞙犾澑 鞚胳劶韹半笇 靸� 瓿勴殟鞐� 霐半澕 靸堧 毂勳毄霅� 歆侅洂 1氇呾棎瓴� 14,000欤� 欤检嫕 毵れ垬 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 鞓奠厴鞚� 頄夓偓臧�瓴╈潃 欤茧嫻 1.19雼煬搿�, 攵�鞐澕 膦呹皜鞕� 霃欖澕頃╇媹雼�. 鞓奠厴鞚� 10雲� 毵岅赴鞚措┌ 4雲勱皠 氩犾姢韺� 臁瓣贝鞚� 臧�歆�瓿� 鞛堨溂氅�, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 75%電� 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺悩氅� 瓿勳啀 攴茧毳� 臁瓣贝鞙茧 頃╇媹雼�.
Zentalis Pharmaceuticals (Nasdaq : ZNTL), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans le d茅veloppement d'un inhibiteur WEE1 pour le cancer de l'ovaire et d'autres types de tumeurs, a annonc茅 une attribution d'incitation conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq.
Le comit茅 de r茅mun茅ration de la soci茅t茅 a accord茅 des options d'achat de 14 000 actions 脿 un nouvel employ茅 dans le cadre du Plan d'incitation 脿 l'embauche 2022. Les options ont un prix d'exercice de 1,19 $ par action, correspondant au cours de cl么ture 脿 la date d'attribution. Les options pr茅sentent une dur茅e de 10 ans avec une acquisition des droits sur quatre ans, incluant 25 % acquis apr猫s la premi猫re ann茅e et les 75 % restants acquis mensuellement sur trois ans, sous r茅serve de la poursuite de l'emploi.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung eines WEE1-Inhibitors f眉r Eierstockkrebs und andere Tumorarten spezialisiert hat, hat eine Anreizzuteilung gem盲脽 Nasdaq-Listing-Regel 5635(c)(4) angek眉ndigt.
Der Verg眉tungsausschuss des Unternehmens hat einem neu eingestellten Mitarbeiter Aktienoptionen zum Kauf von 14.000 Aktien im Rahmen des 2022 Employment Inducement Incentive Award Plans gew盲hrt. Die Optionen haben einen Aus眉bungspreis von 1,19 USD pro Aktie, entsprechend dem Schlusskurs am Zuteilungstag. Die Optionen haben eine Laufzeit von 10 Jahren mit einer vierj盲hrigen Vesting-Periode, einschlie脽lich 25 % Vesting nach dem ersten Jahr und den restlichen 75 % monatlich 眉ber drei Jahre, abh盲ngig von der fortgesetzten Besch盲ftigung.
- None.
- None.
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis庐 Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis鈥� Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company鈥檚 common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual鈥檚 entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual鈥檚 entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee鈥檚 continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis庐 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.
For more information, please visit . Follow Zentalis on X/Twitter at @ and on LinkedIn at .
Contact:
Aron Feingold 鈥� VP, IR & Corp Comms
FAQ
What is the exercise price of ZNTL's newly granted stock options?
How many shares were included in ZNTL's inducement grant?
What is the vesting schedule for ZNTL's inducement grant stock options?
What is Zentalis Pharmaceuticals' main product focus?
